Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Translational Research in Clinical Oncology (TRACO)

TRACO FINAL EXAMINATION (DECEMBER 16, 2008)

Numerous students have requested a certificate upon completion of TRACO.  In order to obtain the certificate you must answer 17 of the 25 questions the final examination correctly.  In the final examination, 1 question is derived from each of the 1 hour lectures. 

For the following 25 questions, please provide the best lettered answer for the numbered question:  If a is the  best answer, click (a).  If b is the best answer, click (b).  If c is the best answer, click (c).  If a, b and c are correct, click (d).  If neither a,b or c are correct, click (e).  You may choose only one lettered answer for each of the 25 numbered questions.  There is no time limit of the examination, however, it must be completed in one setting, so you cannot save your work.  The exam is open-book and open-notes.


Full Name: (to appear on your certificate)

  1. Gleevec:

    A  inhibits the Bcr/Abl tyrosine kinase
    B  is effective in patients with lung cancer
    C  is never refractory in patients with CML
    D  all of the above
    E  none of the above

  2. Small Cell Lung Cancer is:

    A  an epithelial tumor
    B  is not detected with a chest x-ray
    C  is not associated with cigarette smoking
    D  all of the above
    E  none of the above

  3. Which type of clinical trial focuses on drug effectiveness:

    A  phase III
    B  phase II
    C  phase I
    D  all of the above
    E  none of the above

  4. Small molecule inhibitors include:

    A  Herceptin
    B  Gefitinib
    C  Bevacizumab
    D  all of the above
    E  none of the above

  5. HIV attachment and entry is regulated by:

    A  gp120
    B  CD4
    C  CXCR4
    D  all of the above
    E  none of the above

  6. In metastasis, the cancer cell must:

    A  escape from the primary tumor
    B  enter the vascular or lymphatic system
    C  survive in a new organ
    D  all of the above
    E  none of the above

  7. Ovarian cancer: 

    A  is frequently detected in stage I
    B  is treated with gefitinib
    C  has a BRCA-1 linked hereditary component
    D  all of the above
    E  none of the above

  8. Angiogenesis:

    A  is inhibited by thrombospondin-1
    B  is stimulated by VEGF
    C  has leaky tumor blood vessels
    D  all of the above
    E  none of the above

  9. Prostate cancer:

    A  is estrogen dependent
    B  is characterized by rapidly growing tumors
    C  is scored by the Gleason grade
    D  all of the above
    E  none of the above

  10. Imaging tumors:

    A  requires the use of radioisotopes
    B  can be done using MRI
    C  requires no knowledge of the vasculature
    D  all of the above
    E  none of the above

  11. Genomic data:

    A  can be analyzed by artificial neural networks
    B  can be used to determine cancer subtypes
    C  can be used to determine cancer treatment
    D  all of the above
    E  none of the above

  12. Breast cancer:

    A  is usually treated with chemotherapy
    B  is usually treated with lapatinib
    C  is usually treated with luteinizing hormone releasing analog
    D  all of the above
    E  none of the above

  13. Radiation therapy:

    A  works well in hypoxic tumors
    B  targets DNA
    C  is not sensitized by taxanes
    D  all of the above
    E  none of the above

  14. Which of the following increases the risk of getting colorectal cancer:

    A  obesity
    B  physical actitivy
    C  aspirin use
    D  all of the above
    E  none of the above

  15. COX-2 inhibitors include:

    A  zileuton
    B  budesonide
    C  celecoxib
    D  all of the above
    E  none of the above

  16. Adoptive immunotherapy involves:

    A  coupling toxins to mAbs
    B  using tumor infiltrating lymphocytes
    C  using sensitized T cells
    D  all of the above
    E  none of the above

  17. Non-Hodgkin’s lymphoma:

    A  accounts for 50% of all new cancer cases
    B  includes follicular lymphoma
    C  can be treated with herceptin
    D  all of the above
    E  none of the above

  18. RNA interference:

    A  involves dsRNA mediated gene silencing
    B  is mediated by RISC
    C  using sensitized T cells
    D  all of the above
    E  none of the above

  19. Tumor suppressor genes can be silenced by:

    A  methylation
    B  acetylation
    C  u.v. light
    D  all of the above
    E  none of the above

  20. Inflammation is associated with generation of:

    A  cytokines
    B  prostaglandins
    C  reactive nitrogen species
    D  all of the above
    E  none of the above

  21. Epidemiological studies:

    A  determine the cancer treatment
    B  assess efficacy of public health interventions
    C  identify the causes of death
    D  all of the above
    E  none of the above

  22. Cervical cancer:

    A  is caused by papilloma virus
    B  is not encoded by L1
    C  is best treated with vaccine in adults over 20 years of age
    D  all of the above
    E  none of the above

  23. Vaccines:

    A  are a recent scientific research
    B  recognize lung cancer cells as foreign
    C  are not used to treat infectious diseases
    D  all of the above
    E  none of the above

  24. Stem cells:

    A  are present in cancer tumors
    B  are self-renewing
    C  are characterized by markers such as CD29
    D  all of the above
    E  none of the above

  25. Cancer health disparities result:

    A  from good nutrition
    B  a decreased incidence of prostate cancer in African American males
    C  a decreased breast cancer mortality in African American females
    D  all of the above
    E  none of the above


    Please review your answers and make any changes that needed. If you are done, please submit your answers and your exam will be computer graded. If you answer 70% of the questions correct, you will be forwarded to the course evaluation.

TRACO Examination is currently Closed.